Article Information
History
- August 6, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Lidya Handayani Tjan1,*,
- Tatsuya Nagano2,*,
- Koichi Furukawa1,
- Mitsuhiro Nishimura1,
- Jun Arii1,
- Sayo Fujinaka3,
- Sachiyo Iwata4,
- Yoshihiro Nishimura2 and
- Yasuko Mori1
- 1Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
- 2Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
- 3Clinical Laboratory Department, Hyogo Prefectural Kakogawa Medical Center, Kakogawa, Japan
- 4Division of Cardiovascular Medicine, Hyogo Prefectural Kakogawa Medical Center, Kakogawa, Japan
- Corresponding author:
Yasuko Mori, MD, PhD Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Hyogo 650-0017, Japan. Tel: +81-78-382-6272, Fax: +81-78-382-6879 E-mail: ymori{at}med.kobe-u.ac.jp
↵* These authors contribute equally to the work
Posted August 06, 2020.
The Trend of Neutralizing Antibody Response Against SARS-CoV-2 and the Cytokine/Chemokine Release in Patients with Differing Severities of COVID-19: All Individuals Infected with SARS-CoV-2 Obtained Neutralizing Antibody
